Alpha 1-antitrypsin deficiency secondary prevention: Difference between revisions
Irfan Dotani (talk | contribs) No edit summary |
No edit summary |
||
| (9 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Alpha 1-antitrypsin deficiency}} | {{Alpha 1-antitrypsin deficiency}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}}{{Mazia}} | ||
{{ | |||
==Overview== | ==Overview== | ||
[[Secondary prevention]] strategies following alpha1-antitrypsin deficiency (AATD) includes advising the [[patient]] to avoid [[Cigarettes|cigarette]] [[smoking]]. [[Smoking]] accelerates the progression of [[emphysema]] in severely deficient individuals by as much as 15 years when compared to their nonsmoking controls. [[Pneumonia]] and annual [[influenza]] [[vaccines]] will help prevent [[respiratory]] [[infections]] in patients with alpha1-antitrypsin deficiency (AATD).The ATS/ERS AAT Deficiency Task Force recommends that all exacerbations with [[purulent]] [[sputum]] be treated with early [[antibiotic]] [[therapy]]. Prompt and effective treatment of [[infections]] may provide protection from additional [[lung]] [[injury]] from an influx of [[neutrophils]] into the [[alveolus]]. | |||
==Secondary Prevention== | ==Secondary Prevention== | ||
[[Secondary prevention]] strategies following alpha1-antitrypsin deficiency (AATD) includes :<ref name="pmid18565211">{{cite journal |vauthors=Fregonese L, Stolk J |title=Hereditary alpha-1-antitrypsin deficiency and its clinical consequences |journal=Orphanet J Rare Dis |volume=3 |issue= |pages=16 |year=2008 |pmid=18565211 |pmc=2441617 |doi=10.1186/1750-1172-3-16 |url=}}</ref><ref name="pmid16456382">{{cite journal |vauthors=Abusriwil H, Stockley RA |title=Alpha-1-antitrypsin replacement therapy: current status |journal=Curr Opin Pulm Med |volume=12 |issue=2 |pages=125–31 |year=2006 |pmid=16456382 |doi=10.1097/01.mcp.0000208452.57854.c6 |url=}}</ref> | |||
*The most effective [[secondary prevention]] strategy for alpha1-antitrypsin deficiency (AATD) patient is to avoid [[cigarette smoking]]. [[Smoking]] accelerates the progression of [[emphysema]] in severely deficient individuals by as much as 15 years when compared to their nonsmoking [[Control|controls]]. | |||
*[[Pneumonia]] and annual [[influenza]] [[vaccines]] will help prevent [[respiratory]] [[infections]] in [[patients]] with alpha1-antitrypsin deficiency (AATD). | |||
*The ATS/ERS AAT Deficiency Task Force recommends that all exacerbations with [[purulent]] [[sputum]] be treated with early [[antibiotic]] [[therapy]]. Prompt and effective [[Treatments|treatment]] of [[infections]] may provide protection from additional [[lung]] injury from an influx of [[neutrophils]] into the [[alveolus]]. | |||
==References== | ==References== | ||
Latest revision as of 18:03, 22 January 2018
|
Alpha 1-antitrypsin deficiency Microchapters |
|
Differentiating Alpha 1-antitrypsin deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Alpha 1-antitrypsin deficiency secondary prevention On the Web |
|
American Roentgen Ray Society Images of Alpha 1-antitrypsin deficiency secondary prevention |
|
Alpha 1-antitrypsin deficiency secondary prevention in the news |
|
Blogs on Alpha 1-antitrypsin deficiency secondary prevention |
|
Directions to Hospitals Treating Alpha 1-antitrypsin deficiency |
|
Risk calculators and risk factors for Alpha 1-antitrypsin deficiency secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mazia Fatima, MBBS [2]
Overview
Secondary prevention strategies following alpha1-antitrypsin deficiency (AATD) includes advising the patient to avoid cigarette smoking. Smoking accelerates the progression of emphysema in severely deficient individuals by as much as 15 years when compared to their nonsmoking controls. Pneumonia and annual influenza vaccines will help prevent respiratory infections in patients with alpha1-antitrypsin deficiency (AATD).The ATS/ERS AAT Deficiency Task Force recommends that all exacerbations with purulent sputum be treated with early antibiotic therapy. Prompt and effective treatment of infections may provide protection from additional lung injury from an influx of neutrophils into the alveolus.
Secondary Prevention
Secondary prevention strategies following alpha1-antitrypsin deficiency (AATD) includes :[1][2]
- The most effective secondary prevention strategy for alpha1-antitrypsin deficiency (AATD) patient is to avoid cigarette smoking. Smoking accelerates the progression of emphysema in severely deficient individuals by as much as 15 years when compared to their nonsmoking controls.
- Pneumonia and annual influenza vaccines will help prevent respiratory infections in patients with alpha1-antitrypsin deficiency (AATD).
- The ATS/ERS AAT Deficiency Task Force recommends that all exacerbations with purulent sputum be treated with early antibiotic therapy. Prompt and effective treatment of infections may provide protection from additional lung injury from an influx of neutrophils into the alveolus.
References
- ↑ Fregonese L, Stolk J (2008). "Hereditary alpha-1-antitrypsin deficiency and its clinical consequences". Orphanet J Rare Dis. 3: 16. doi:10.1186/1750-1172-3-16. PMC 2441617. PMID 18565211.
- ↑ Abusriwil H, Stockley RA (2006). "Alpha-1-antitrypsin replacement therapy: current status". Curr Opin Pulm Med. 12 (2): 125–31. doi:10.1097/01.mcp.0000208452.57854.c6. PMID 16456382.